Defecetive Drugs: adrugrecall.com
NEWS
Sign up for our newsletter
to receive breaking news about drugs to watch
Contact A Lawyer
Near You
Contact us today for a complimentary consultation with a qualified attorney near you.
Subscribe To Our Syndicated NewsElan and Wyeth Shares Drop Due to Risks
-July 30, 2008
According to recent reports, shares of Elan and Wyeth’s new Alzheimer drug have dropped since risks linked to the medication were announced.
The drug has shown there is an increased risk of serious side effects for patients, though it has shown to be beneficial in people who do not have a genetic risk for the disease.
Investors Pay Attention to Drug Risks
Investors are apparently keeping a close watch on the drug in question, bapineuzumab, since Elan’s New York shares have fallen more than 30 percent in recent weeks.
Meanwhile, Wyeth’s shares have reportedly dropped more than 10 percent.
“If the drug shows a benefit, the risk-benefit ratio will be worth the side effects,” says Dr. Scott Turner, the director of the Memory Disorders Program at Georgetown University Medical Center.
Update on Drug Goes Public
The recent update given on bapineuzumab claims the drug could be the first to modify the course of Alzheimer’s disease, as opposed to simply offering a temporary relief.
However, researchers are still unaware of how serious the risks linked to the medication could be long-term.
Until the severities of the risks are determined, doctors, patients and investors continue to be cautious.
(Source: The New York Times)
Have you been harmed by a drug? If so, please contact us to speak with an experienced and trustworthy attorney who will evaluate your case and ensure you receive the legal guidance and support you need and deserve.
